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OBJECTIVE—Progenitor cells (PCs) contribute to postnatal
neovascularization and tissue repair. Here, we explore the mech-
anism contributing to decreased diabetic circulating PC number
and propose a novel treatment to restore circulating PC number,
peripheral neovascularization, and tissue healing.
RESEARCH DESIGN AND METHODS—Cutaneous wounds
were created on wild-type (C57BL/J6) and diabetic (Lepr
db/db)
mice. Blood and bone marrow PCs were collected at multiple
time points.
RESULTS—Signiﬁcantly delayed wound closure in diabetic
animals was associated with diminished circulating PC number
(1.9-fold increase vs. 7.6-fold increase in lin
/sca-1
/ckit
 in
wild-type mice; P  0.01), despite adequate numbers of PCs in
the bone marrow at baseline (14.4  3.2% lin
/ckit
/sca1
 vs.
13.5  2.8% in wild-type). Normal bone marrow PC mobilization
in response to peripheral wounding occurred after a necessary
switch in bone marrow stromal cell-derived factor-1 (SDF-1)
expression (40% reduction, P  0.01). In contrast, a failed switch
mechanism in diabetic bone marrow SDF-1 expression (2.8%
reduction) resulted in impaired PC mobilization. Restoring the
bone marrow SDF-1 switch (54% reduction, P  0.01) with
plerixafor (Mozobil, formerly known as AMD3100) increased
circulating diabetic PC numbers (6.8  2.0-fold increase in
lin
/ckit
, P  0.05) and signiﬁcantly improved diabetic wound
closure compared with sham-treated controls (32.9  5.0% vs.
11.9  3% at day 7, P  0.05; 73.0  6.4% vs. 36.5  7% at day 14,
P  0.05; and 88.0  5.7% vs. 66.7  5% at day 21, P  0.05,
respectively).
CONCLUSIONS—Successful ischemia-induced bone marrow
PC mobilization is mediated by a switch in bone marrow SDF-1
levels. In diabetes, this switch fails to occur. Plerixafor repre-
sents a potential therapeutic agent for improving ischemia-
mediated pathology associated with diabetes by reducing bone
marrow SDF-1, restoring normal PC mobilization and tissue
healing. Diabetes 59:1974–1983, 2010
A
dult bone marrow-derived progenitor cells
(PCs) contribute to peripheral tissue repair and
regeneration. Vasculogenic PCs mobilize from
the bone marrow and participate in new blood
vessel formation in a variety of physiologic and pathologic
processes, such as wound healing, fracture repair, and
myocardial revascularization (1–3). Since vasculogenic
PCs contribute to nearly a third of new blood vessels in
healing tissues, impaired PC response to injury may con-
tribute to microangiopathic conditions (1,4).
We and others have previously demonstrated that dia-
betic vasculogenic PC dysfunction (i.e., impaired adhe-
sion, proliferation, migration, tubule formation) impairs
new blood vessel formation (5,6). Functional limitations
alone, however, are unlikely to account for the magnitude
of diabetic vasculopathy and wound-healing complica-
tions. Recent reports suggest that diabetic animals and
humans exhibit fewer numbers of circulating vasculogenic
PCs (5,7,8). For example, we have shown that type II
diabetic animals contain signiﬁcantly fewer circulating
PCs at homeostasis and after cutaneous ischemia or
excisional wounding (4,9). Others have noted diminished
numbers of circulating PCs in type I diabetic animals after
ischemic injury (7).
Whether circulating PC depletion is involved in the
pathogenesis of delayed diabetic wound healing remains
unknown. Peripheral injury normally stimulates bone
marrow PC proliferation through cytokine-mediated sig-
nals (e.g., stem cell factor [SCF]) (10), whereas PC
mobilization is mediated by other chemokinetic pro-
teins such as matrix-metalloproteinase-9 (MMP-9) and
stromal cell-derived factor-1- (SDF-1) (11–15). Re-
cently, it has been demonstrated that modulation of
bone marrow–SDF-1 levels with mobilizing agents
5-ﬂuorouracil and granulocyte colony-stimulating factor
induces PC mobilization (13–15), but whether this mo-
bilization mechanism occurs physiologically remains
unknown. Herein, we investigate the relationship be-
tween circulating vasculogenic PCs and diabetic wound
closure; moreover, we explore the cause of diminished
vasculogenic PCs in diabetic patients as well as the
physiologic mechanism regulating PC release from the
bone marrow. We hypothesize that impaired peripheral
diabetic wound healing stems from a dysfunction in the
central SDF-1 switch mechanism responsible for PC
mobilization in the bone marrow.
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Mice and wounding model. C57BL/6J (#664) wild-type and type II diabetic
mice homozygous for Lepr
db (#642) age 8–12 weeks were purchased from
Jackson Laboratories (Bar Harbor, ME). As previously described, these
diabetic mice have persistently elevated weights and signiﬁcantly elevated
blood glucose levels compared with their wild-type controls (16,17). To
conﬁrm that mice used in this model were diabetic, fasting glucose levels of
both wild-type and diabetic mice were measured using an AccuCheck
Advantage glucometer and AccuCheck comfort strips (Roche; Branchburg,
NJ). The body weights of the mice were also measured.
Cutaneous wounding was achieved by creating dorsal skin ﬂaps or
excisional wounds as previously described (4,18). Brieﬂy, two 6-mm full-
thickness wounds extending through the panniculus carnosus layer were
excised from the dorsum of mice using a sterile circular punch biopsy (Fig.
1A) (Sklar Instruments; West Chester, PA). A silicone stent was secured
around the perimeter of the wound to limit wound contracture (Fig. 1B). Time
to closure, deﬁned as the number of days for complete re-epithelialization, and
percent wound closure, calculated as (1-[wound area]/[original wound area]),
of excisional wounds were measured using photogrammetry. Digital photo-
graphs were taken on the day of wounding and every 7 days thereafter.
Photographs were acquired with a 7-megapixel digital camera (Canon USA,
Lake Success, NY) from a distance of 6.5 cm, with the lens oriented parallel to
the wound. The wound area was measured using a digital selection (Photo-
shop CS3, Adobe Systems; San Jose, CA) and calibrated against the internal
diameter of the silicon splint to correct for any subtle magniﬁcation, perspec-
tive, or parallax effect on the image. Ten animals were wounded in each
experimental group studied. All experiments were performed in accordance
with the New York University Medical Center Institutional Animal Care and
Use Committee (IACUC#041104).
Isolation of peripheral and bone marrow mononuclear cells. Peripheral
blood was obtained by intracardiac puncture at baseline, 2, 7, and 10 days
after ischemia (n  8 for each time point). Bone marrow was obtained by
ﬂushing each femur, tibia, humerus, and pelvis with PBS/10% FBS/5% EDTA
(6,19). Peripheral blood and bone marrow mononuclear cells (MNCs) were
separated by density gradient centrifugation with Histopaque 1,083 (Sigma,
St. Louis, MO).
Magnetic sorting and ﬂow cytometry. Bone marrow PCs were magneti-
cally separated from total bone marrow MNCs (Miltenyi Biotech, Auburn, CA).
Cells were labeled with a lineage depletion cocktail (biotinylated anti CD5,
CD45R (B220), CD11b, Gr-1 (Ly-6G/C), 7–4, and Ter-119 antibodies) in a 1:60
dilution, and secondary antibiotin microbeads (1:10). For characterization by
ﬂow cytometry, peripheral blood and bone marrow MNCs were stained with
rat anti-mouse antibodies (ﬂuorescein isothiocyanate-conjugated Ly-6A/E
[1:100], phycoerythrin-conjugated VEFG-R2 [1:50], phycoerythrin-conjugated
CXCR4 [1:100], allophycocyanin-conjugated CD117 [1:100], biotin-conjugated
lineage depletion cocktail [1:20], and strepavidin-phycoerythrin-conjugated-
Cy7 [1:200]) (BD Bioscience, San Jose, CA, and Miltenyi Biotech). All
antibodies were titrated and optimized for appropriate detection. Cells were
costained with 7-aminoactinomycin D (Invitrogen, Carlsbad, CA) to detect
nonviable cells. Samples were collected using a BD FACSCaliber ﬂow
cytometer (Becton Dickinson, Franklin Lakes, NJ), and analyses were per-
formed with FlowJo 8.0 software (TreeStar Inc., Ashland, OR) to delineate
lin
/sca-1
(L
S
), lin
/ckit
 (L
C
), and lin
/ckit
/sca1
 (L
C
S
) popula-
tions of peripheral blood and bone marrow MNCs.
Chemotaxis assay. Recombinant mouse SDF-1 (250 ng/ml) (Peprotech,
Rocky Hill, NJ) or saline was added to the bottom of 24-well plates (600 l).
Cells (5 	 10
4/100 l) were suspended in EBM-2/10% FBS and seeded onto the
membranes of Transwell inserts (5 m pore) (Costar, Corning, NY). Assays
were run in quadruplicate for5ha t37°C. The surface of the membranes was
scraped with cotton swabs, ﬁxed with 1% PFA, and mounted onto slides with
DAPI-stained Vectashield (Vector, Burlingame, CA). Photographs were taken
at 	4 magniﬁcation and the number of cells was quantiﬁed with a Kodak ID
3.5 Image Processor (Rochester, NY).
Proliferation assay. PCs (2 	 10
4/100 l) suspended in EBM-2/10%FBS were
seeded onto 96-well plates in quadruplicate. An additional 100 l of SCF (100
ng/ml) or control media was added to each well. Plates were incubated at 37°C
for 18 h. Bromodeoxyuridine (BrdU) reagent (BrdU Cell Proliferation Assay,
Chemicon, Billerica, MA) was then added for 4 h, and proliferation was
quantiﬁed with a spectrometer as a relative proliferation index.
Supplemented mobilization model. Ten days after wounding, wild-type and
diabetic animals received the CXCR4 partial agonist Plerixafor (5 mg/kg;
Sigma; n  15) or PBS (n  15) by subcutaneous injection 60 min before kill.
Additional wild-type and diabetic animals received daily Plerixafor (n  15) or
PBS (n  15) intraperitoneal injections beginning 3 days after wounding and
continuing until time of wound closure.
ELISA protein quantiﬁcation. SDF-1 protein levels were assessed by
enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis,
MN). Serum samples (from density gradient centrifugation) and bone marrow
samples (from 500 l of PBS ﬂush) were run in triplicate and standardized
with a BCA Protein Assay Kit (Pierce, Rockford, IL).
Statistical analysis. All data represent mean  SEM. Pairwise comparisons
between groups were assessed by Student t test. A one-way ANOVA and
Tukey-Kramer post hoc analysis were performed when comparisons involved
more than two groups. Signiﬁcance was considered to be P  0.05. The
number of animals needed to demonstrate a signiﬁcant difference between
experimental groups with a power greater than 0.80 was calculated using
G*Power (G*Power, Melbourne, Australia).
RESULTS
Diabetes signiﬁcantly impairs cutaneous wound clo-
sure. The diabetic mice used in all experiments had
signiﬁcantly elevated serum glucose levels (485.7  2.0
mg/dl vs. 140.3  0.3 mg/dl, P  0.01) and body weight
(57.9  0.1g vs. 25.9  0.1g, P  0.01) compared with
age-matched wild-type mice.
Using an established excisional wound healing model,
we demonstrated that a single punch biopsy produces a
defect size of 6.1  0.2 mm (Fig. 1A–C). Diabetic mice
demonstrated signiﬁcantly delayed rate of wound closure
compared with wild-type animals (11.9  3.0% vs. 47.5 
3.9% at day 7, P  0.01; 36.5  7.0% vs. 97.5  1.8% at day
14, P  0.001; and 66.7  5.0% vs. 100  0% at day 21, P 
0.01) (Fig. 1D). The average time to wound closure in
wild-type animals was 15.0  0.3 days. In contrast, the
average time to wound closure in diabetic animals was
signiﬁcantly longer (26.4  1.9 days; P  0.01).
Impaired diabetic wound closure is associated with
fewer circulating vasculogenic PCs. Having demon-
strated that diabetic animals exhibit impaired cutaneous
wound closure, we measured the number of circulating
vasculogenic PCs in wild-type and diabetic animals during
active wound healing. Two days after cutaneous wound-
ing, wild-type animals had a moderate increase in circu-
lating vasculogenic PCs compared with homeostatic levels
(23.8  2.0% vs. 13.5  0.6% L
S
, P  0.05; 3.1  0.1% vs.
2.1  0.3% L
C
, P  0.05; 1.3  0.1 vs. 0.5  0.1%
L
S
C
, P  0.01) (Fig. 2A and B). Seven days after
wounding, circulating vasculogenic PCs in wild-type ani-
mals remained elevated (27.6  1.8% L
S
, P  0.01; 2.1 
0.1% L
C
; 1.3  0.2 l
S
C
, P  0.01). The increase in
wild-type circulating vasculogenic PCs was most pro-
nounced at day 10 (32.2  1.1% L
S
, P  0.01; 7.4  0.9%
L
C
, P  0.01; 4.0  0.7% L
S
C
, P  0.01). In marked
contrast, diabetic wounding led to a less substantive
response in circulating diabetic vasculogenic PCs at iden-
tical time points: baseline (7.9  1.2% L
S
, 1.7  0.3%
L
C
, 0.5  0.2% L
S
C
), day 2 (13.1  2.6% L
S
, P 
0.05; 2.4  0.2% L
C
, P  0.05; 1.6  0.4% L
S
C
, P 
0.05), day 7 (15.6  1.6% L
S
, P  0.05; 3.7  0.9% L
C
,
P  0.05; 0.8  0.5% L
S
C
), and day 10 (12.3  1.2%
L
S
, P  0.05; 2.3  0.4% L
C
, 1.0  0.2% L
S
C
, P 
0.05). The greatest difference between wild-type and dia-
betic circulating vasculogenic PC was observed 10 days
after cutaneous wounding (32.2  1.1% vs. 12.3  1.2%
L
S
, P  0.01; 7.4  0.9% vs. 2.3  0.4% L
C
, P  0.05;
4.0  0.7% vs. 1.0  0.2% L
S
C
, P  0.01, respectively).
Diabetic bone marrow contains adequate numbers of
vasculogenic PCs at baseline and in response to
cutaneous wounding. Since diabetic mice showed im-
paired cutaneous wound closure and fewer circulating
vasculogenic PCs associated with impaired healing, we
also investigated the number of PCs in wild-type and
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FIG. 1. Diabetic mice experience delayed wound closure compared with wild-type mice. A: A 6-mm punch biopsy was performed on the dorsal
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cence-activated cell sorter analysis demonstrated fewer
numbers of certain PC populations at baseline in wild-type
compared with diabetic mice (19.4  3.9% vs. 33.9  2.0%
L
S
, P  0.05; 8.3  1.3% vs. 13.4  2.1% L
C
, P  0.08;
and 1.7  0.3% vs. 5.6  0.6% L
S
C
, P  0.01) (Fig. 3A
and B). After cutaneous wounding, wild-type bone marrow
PC number increased markedly: day 2 (32.7  2.2% L
S
,
P  0.01; 11.5  0.5% L
C
, P  0.05; 4.1  0.3% L
S
C
,
P  0.01), day 7 (60.4  3.2% L
S
, P  0.01; 15.4  2.2%
L
C
, P  0.01; 9.5  1.3% L
S
C
, P  0.01), and day 10
(44.1  4.8% L
S
, P  0.01; 17.1  1.2% L
C
, P  0.01;
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FIG. 2. Peripheral ischemia and circulating PC number. A: Peripheral
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*P < 0.05; **P < 0.01. (A high-quality color digital representation of
this ﬁgure is available in the online issue.)
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(A high-quality color digital representation of this ﬁgure is available in
the online issue.)
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S
C
, P  0.05). In a similar fashion,
diabetic bone marrow PCs proliferated in response to
cutaneous wounding: day 2 (45.3  2.9% L
S
, P  0.01;
18.8  0.7% L
C
, P  0.05; 9.5  0.7% L
S
C
, P  0.01)
day 7 (51.1  3.9% L
S
, P  0.01; 23.1  4.1% L
C
, P 
0.05; 17.4  3.0 and L
S
C
, P  0.01) and day 10 (59.9 
2.6% L
S
, P  0.01; 14.3  2.6% L
C
; 14.4  3.2%
L
S
C
, P  0.05).
Diabetic and wild type bone marrow vasculogenic
PCs have similar functional capabilities. Since wild-
type and diabetic animals had a similar number of bone
marrow PCs at baseline and in response to cutaneous
wounding, we examined the functional capacity of wild-
type and diabetic bone marrow PCs. We ﬁrst studied the
effects of cutaneous injury on bone marrow PC prolifera-
tion; wild-type bone marrow PC proliferation remained at
baseline levels for 2 days (1.0  0.3-fold increase from
baseline), but increased signiﬁcantly by day 7 (2.3 
0.1-fold increase, P  0.01). Diabetic bone marrow PC
proliferation increased substantially at 2 days (3.3 
0.2-fold increase from baseline, P  0.01) after cutaneous
wounding and continued to remain elevated through day 7
(3.2  0.1-fold increase, P  0.01) (Fig. 4A).
We next investigated the effects of SCF, a key PC growth
factor, (10,20) on wild-type and diabetic bone marrow PC
proliferation. SCF treatment of wild-type and diabetic
bone marrow PCs before cutaneous wounding induced a
3.1  0.5-fold and 2.8  0.4-fold increase in proliferation in
both wild-type and diabetic bone marrow PCs, respec-
tively (P  0.01). Similarly, SCF treatment induced a 2.5 
0.2-fold and 2.7  0.6-fold increase in wild-type and
diabetic bone marrow PCs 7 days after cutaneous wound-
ing (P  0.01) (Fig. 4B).
Next, we examined the migratory ability of wild-type
and diabetic bone marrow PCs. Bone marrow PCs isolated
from wild-type and diabetic animals migrated equally
effectively to SDF-1 (wild-type 246  25 cells/HPF, P 
0.05; diabetic 250  46, P  0.05) (Fig. 4C). Similarly, no
change was noted in the migratory ability of bone marrow
PCs isolated from diabetic and wild-type mice after isch-
emia (data not shown).
The bone marrow SDF-1 switch-mechanism is dys-
functional in diabetic mice. Since diabetic bone marrow
contains an adequate number of functional PCs, we next
investigated potential mechanisms responsible for the
impaired mobilization of vasculogenic PCs into the circu-
lation. SDF-1 is a key bone marrow PC mobilizing factor
(12–15); therefore, we assayed serum and bone marrow
SDF-1 levels in wild-type and diabetic mice. Serum
SDF-1 levels were not signiﬁcantly different in wild-type
compared with diabetic mice before (340  50 vs. 430  40
pg/ml) or after cutaneous wounding (1,008  240 vs. 420 
80 pg/ml at day 2; 520  150 vs. 870  190 pg/ml at day 7;
and 360  50 vs. 390  60 pg/ml at day 10) (Fig. 5A).
However, based on recent evidence that bone marrow,
rather than serum, SDF-1 expression may be involved in
granulocyte colony-stimulating factor (G-CSF) and 5-ﬂu-
orouracil (5-FU) mediated PC mobilization, (15,21) we
hypothesized that bone marrow SDF-1 may act as a
switch to regulate PC release after cutaneous wounding.
Seven days after cutaneous wounding, wild-type bone
marrow SDF-1 expression decreased precipitously
(640  110 pg/ml vs. 1,007  210 pg/ml at baseline, P 
0.01). This change in bone marrow SDF-1 expression
immediately preceded the most pronounced increase (day
10) in wild-type circulating vasculogenic PCs (Fig. 2A–C).
In marked contrast, diabetic bone marrow SDF-1 expres-
sion remained constant (1,000  170 pg/ml at baseline,
1,400  120 at day 2, 1,390  210 at day 7, and 1,140  130
at day 10) (Fig. 5B).
Plerixafor corrects the diabetic bone marrow SDF-1
switch and restores PC mobilization. Having found that
a switch in wild-type bone marrow SDF-1 expression
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remained at baseline for 2 days after cutaneous injury, but increased
signiﬁcantly by day 7. Diabetic bone marrow PC proliferation, however,
signiﬁcantly increased by day 2 after wounding and remained elevated
through day 7. B: After SCF treatment, BrdU assay demonstrated that
wild-type and diabetic bone marrow PC number increased appropri-
ately both before cutaneous wounding (day 0) and 7 days after
cutaneous wounding. (Data for Fig. 4A and B are presented as fold
change from baseline, where baseline values are equal to 1.) C: The
migratory response of PCs to SDF-1 in vitro was not signiﬁcantly
different in wild-type and diabetic animals. Representative photomi-
crographs of transwell membranes with DAPI-stained PCs are shown.
CNTRL, control; n.s., not signiﬁcant; *P < 0.05; **P < 0.01. (A
high-quality color digital representation of this ﬁgure is available in
the online issue.)
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effects of the SDF-1 receptor (CXCR4) partial agonist,
plerixafor, on serum and bone marrow SDF-1 levels.
Treatment of nonwounded wild-type and diabetic mice
with plerixafor resulted in a rise in serum SDF-1 (1,940 
150 vs. 367  33 pg/ml, P  0.01; 1,880  300 vs. 380  45
pg/ml, P  0.01, respectively) similar to the rise in serum
SDF-1 postcutaneous wounding (Fig. 6A). Likewise, bone
marrow levels of SDF-1 signiﬁcantly declined in both
wild-type and diabetic animals treated with plerixafor 10
days after wounding (820  10 vs. 1,180  200 pg/ml, P 
0.05; 520  20 vs. 1,140  130 pg/ml, P  0.01, respec-
tively) (Fig. 6B). Finally, a single dose of plerixafor admin-
istered 10 days after cutaneous injury led to increased
bone marrow PC mobilization in wild-type (1.9  0.1-fold
increase in L
S
, P  0.01; 7.5  0.5-fold increase in
L
C
, P  0.01; 3.7  1.0-fold increase in L
S
C
, P 
0.05) and diabetic mice (3.6  0.1-fold increase in L
S
,
P  0.01; 6.0  1.8-fold increase in L
C
, P  0.05; 4.5 
1.7-fold increase in L
S
C
, P  0.05) (Fig. 7).
Restoration of diabetic bone marrow PC mobilization
restores wound closure. Since decreased circulating
PCs in diabetic mice is associated with impaired wound
closure, and treatment with plerixafor restored the switch
in bone marrow SDF-1 expression as well as circulating
PC numbers in diabetic mice, we tested the effects of
plerixafor on diabetic wound closure. Although a single
plerixafor intraperitoneal injection did not signiﬁcantly
improve wound closure in either animal model (data not
shown), daily plerixafor intraperitoneal injections im-
proved diabetic percent wound closure compared with
sham-treated diabetic mice at 7, 14, and 21 days (32.9 
5.0% vs. 11.9  3%, P  0.05; 73.0  6.4% vs. 36.5  7%, P 
0.05; and 88.0  5.7% vs. 66.7  5%, P  0.05, respectively)
(Fig. 8A). Additionally, the improvement in plerixafor-
treated diabetic wound closure correlated with an in-
crease in circulating PCs cells (3.7  1.0-fold increase in
L
S
 a t1h ,P  0.01; 11.9  1.7-fold increase in L
S
 at
day 7, P  0.01; and 19.6  1.9-fold increase in L
S
 at day
14, P  0.01) (Fig. 8B).
DISCUSSION
The effects of ischemic injury on circulating PC number
have been well documented in both animal and human
studies (3,12,13,19). In healthy subjects, peripheral isch-
emia leads to a signiﬁcant rise in the number of circulating
PCs, thereby increasing the quantity of PCs that can
participate in tissue repair. With certain clinical condi-
tions, such as diabetes, the quantity of circulating PCs is
reduced (4,6–9). Although it has been shown that diabetic
humans and animals exhibit fewer numbers of circulating
PCs at rest and in response to ischemia, the mechanisms
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FIG. 5. Impaired mobilization of diabetic bone marrow PC. A: Quanti-
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FIG. 6. Effects of plerixafor on postischemic SDF-1 levels and PC
mobilization. A: ELISA of plerixafor-treated animals at day 10 after
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wound healing remain unknown. The present study is the
ﬁrst to report a decline in bone marrow SDF-1 levels as a
key regulator of PC mobilization in response to peripheral
ischemia and further identiﬁes this SDF-1–mediated
pathway as a primary mechanism of insufﬁcient PC mobi-
lization in diabetes. We provide further support that de-
creased numbers of circulating PC results in poor diabetic
wound closure, and also demonstrate that diabetic wound
closure may be improved by restoring this pathway with
the CXCR4 partial agonist, AMD3100 (9).
Our initial experiments demonstrated elevated circulat-
ing PCs in wild-type animals after ischemia (3.6-fold L
C
,
7.6-fold L
S
C
 at day 10), with only minor changes in
circulating PC numbers in diabetic animals (1.4-fold L
C
,
1.9-fold L
S
C
 at day 10). Similar ﬁndings were noted by
Fadini et al., who reported a peak in S
 and S
C
 cells 2
to 3 days after hind-limb ischemia (approximately a four-
fold increase), with no comparable increase in circulating
PCs of type I diabetic animals (22). Although the kinetics
of peak mobilization vary between our study and that of
Fadini et al. (day 10 vs. day 2), we conﬁrm, in a different
model of peripheral ischemia, that type 2 diabetes is
associated with diminished circulating PCs. Additionally,
our ﬁndings offer further evidence that different subpopu-
lations of bone marrow PCs may be mobilized at different
times after peripheral wounding, (23,24) as the lin
/sca-1

population in wild-type mice was mobilized earlier and to
a greater extent than the other populations of PCs com-
pared with diabetic mice (Fig. 2B). Conversely, the num-
ber of PCs found at baseline in the bone marrow and
peripheral blood of wild-type mice correspond with those
reported by Yamamoto et al. (25).
Subsequent analysis indicated that this phenomenon
was not due to differences in the availability of cells from
the bone marrow, as the number of PCs in the bone
marrow did not differ among wild-type and diabetic ani-
mals at any time point studied. Similarly, no differences
were noted in bone marrow PC proliferative capacity.
These data supported our initial hypothesis that fewer
circulating PCs in diabetes is the result of aberrant mech-
anisms of mobilization.
We then explored chemokinetic-signaling pathways that
have been implicated in PC mobilization. Previous reports
suggest that PC mobilization is regulated in part by serum
SDF-1 levels (12,21). Though we observed signiﬁcant
increases in serum SDF-1 in both animal types, we
believe that these changes were not the primary mecha-
nism responsible for PC mobilization. First, maximum
levels of serum SDF-1 in wild-type animals occurred at
day 2 after ischemia, whereas peak PC mobilization oc-
curred at a much later time point (day 10). Second,
diabetic animals achieved levels of serum SDF-1 equal to
wild-type, but did not experience substantial mobilization
of PCs at any time point. Finally, diabetic PCs exhibited a
normal migratory response to SDF-1, as demonstrated by
an in vitro chemotaxis assay.
In contrast to serum SDF-1, bone marrow SDF-1
levels signiﬁcantly affected PC mobilization. Our data
revealed a temporal relationship between changes in bone
marrow SDF-1 and PC mobilization. Wild-type bone
marrow SDF-1 levels declined at day 7 after ischemia,
immediately before mobilization, which subsequently
peaked at day 10. Moreover, a failure of bone marrow
SDF-1 to decrease after peripheral wounding correlated
with the impaired mobilization observed in diabetic ani-
mals. Finally, pharmacologic reduction of bone marrow
SDF-1 levels with plerixafor in both wild-type (32%) and
diabetic (54%, relative to control) animals led to signiﬁcant
PC mobilization.
By investigating both serum and bone marrow SDF-1
levels in relation to PC mobilization, we also addressed
the long-standing question of whether a SDF-1 bone
marrow-to-peripheral blood gradient is necessary for
successful PC mobilization. Previously, De Falco et al.
(12) detected a positive SDF-1 gradient (bone marrow
levels less than peripheral blood levels) in a hind-limb
ischemia model. Others have argued against such a
gradient, claiming that bone marrow levels remain
higher than peripheral blood levels throughout the
mobilization process (14). Although we identiﬁed a
switch in bone marrow SDF-1 expression, a signiﬁcant
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never established in response to peripheral ischemia
alone. Conversely, treatment with plerixafor generated
a 1:2.4 and 1:3.6 SDF-1 gradient (bone marrow:periph-
eral blood), resulting in greater PC mobilization in
wild-type (1.9  0.1-fold increase in L
S
, P  0.01;
7.5  0.5-fold increase in L
C
, P  0.01; 3.7  1.0-fold
increase in L
S
C
, P  0.05) and diabetic mice (3.6 
0.1-fold increase in L
S
, P  0.01; 6.0  1.8-fold
increase in L
C
, P  0.05; 4.5  1.7-fold increase in
L
S
C
, P  0.05) 10 days after cutaneous injury,
respectively. Based on these experiments, we hypothe-
size that a bone marrow:peripheral blood SDF-1 gradi-
ent enhances, but is not critical for, ischemia-induced
PC mobilization.
Although this study demonstrates that a reduction in
bone marrow SDF-1 serves as a critical mechanism for
peripheral ischemia-induced PC mobilization, studies to
investigate quotidian bone marrow SDF-1 regulation are
needed. Moreover, the mechanisms mediating the ob-
served switch in bone marrow SDF-1 remain unknown.
Since much attention has been focused on the inﬂuence of
MMP-9 and kit ligand on PC mobilization, subsequent
studies from our laboratory investigated a potential mech-
anism involving these factors (13,26). To date, we have
been unable to demonstrate a correlation between bone
marrow or serum MMP-9 levels and the impaired SDF-1
switch in diabetic mice (data not shown). One potential
factor may be neutrophil elastase (NE), which has been
shown to break down SDF-1 within the bone marrow
niche (27,28). Although it is possible that diabetic bone
marrow contains less NE, this seems unlikely in light of
previous reports that demonstrate elevated levels of cir-
culating NE in diabetic patients (29,30). It is also plausible
that diabetes affects the functional activity, rather than the
amount, of NE in the bone marrow. Future studies will
help identify the role of various proteinases in bone
marrow SDF-1 stability, as well as their involvement in
diabetic PC mobilization.
In addition to identifying a novel mechanism for normal
and impaired PC mobilization, this study highlights the
potential clinical utility of plerixafor as an agent for PC
augmentation in human patients. Clinical trials are cur-
rently underway to evaluate the efﬁcacy of augmented PC
mobilization and direct PC delivery to sights of vascular
occlusion (31). Ongoing trials with plerixafor are encour-
aging, offering strong evidence for robust mobilization of
proangiogenic cells (32,33). Indeed, our group has found
that plerixafor signiﬁcantly improves time to re-epithelial-
ization (closure) in a diabetic wound model via restoration
of bone marrow PC mobilization. Although a single dose of
plerixafor resulted in reduction of SDF-1 in the bone
marrow and a subsequent release of bone marrow progen-
itor cells, this did not alter the rate of closure in diabetic
animals. This ﬁnding is consistent with previous studies
using our wound healing model in which repeated delivery
of supraphysiologic levels of VEGF was necessary to
document increased rates of closure (9). Moreover, bone
marrow-derived progenitor cells are known to rapidly
return to the bone marrow or extramedullary sites to
replenish progenitor cell populations, (14), and thus it is
not surprising that we did not see physiologic effects on
wound closure after a single dose. Therefore, we choose to
deliver repeated doses of plerixafor based on delivery
protocols that have been previously reported to have a
biologic effect (34). And although these ﬁndings do not
infer that plerixafor results in normal wound healing, we
feel that faster wound closure with this treatment is of
clinical importance.
Although the putative mechanism of plerixafor-medi-
ated PC mobilization is CXCR4 agonism, (35) we identify
an additional physiologic effect of this pharmacologic
agent: a signiﬁcant decrease in bone marrow SDF-1
levels. This ﬁnding is consistent with previous data dem-
onstrating increased progenitor cells mobilization with
G-CSF delivery (15); however, the mechanism by which
plerixafor achieves decreased levels of bone marrow
SDF-1 remains unknown. At present, it is unclear
whether SDF-1 levels decreased through altered mecha-
nisms of translocation, degradation, or some yet unidenti-
ﬁed mechanism (36). Current data suggest an apparent
paradox in the SDF-1–CXCR4 signaling pathway of pro-
genitor cell trafﬁcking. Petit et al. (37) recently proposed
the notion of a “biphasic mobilization pattern” in which
CXCR4 inhibition allows for recruitment of stem cells
from the perivascular niche, whereas activation of CXCR4
promotes the mobilization of stem cells in a different niche
that are tethered to the stroma. Further investigation is
warranted, however, as the long-term effects of plerixafor
treatment on bone marrow and peripheral blood SDF-1
levels remain unknown. Since diabetes impairs the bone
marrow SDF-1 switch after peripheral ischemia and
diabetic patients often require vascular therapeutic inter-
ventions, our ﬁndings offer clinical signiﬁcance for dia-
betic wound healing. Future studies should help elucidate
the therapeutic implications of targeting the bone marrow
SDF-1–vasculogenic PC mechanism to augment diabetic
progenitor cell mobilization.
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